PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
The first-ever quarterly profit at subsidiary Keyprime Research and an expanding order backlog have raised hopes for a second-half earnings rebound, but quarter-to-quarter non-operating volatility and rising financial leverage remain key variables.
Consolidated H1 2026 revenue rose 26% year-on-year to KRW 26.3 billion, while the operating loss narrowed roughly 40% to KRW 2.0 billion.
Non-human primate (NHP) specialist subsidiary Keyprime Research posted its first-ever quarterly operating profit in Q2 2026, with revenue of KRW 5.8 billion and operating profit of KRW 0.4 billion.
Combined order backlog for BioToxTech and Keyprime Research stood at KRW 60.7 billion at the end of H1 2026, with overseas clients accounting for over 60%.
Full-year 2025 net income attributable to owners was a positive KRW 1.2 billion despite an operating loss of KRW 4.8 billion, with sharp swings including a KRW 5.5 billion net profit in Q3 2025 and a KRW 5.8 billion net loss in Q2 2026 driven by non-operating items.
Expectations exist for spillover benefits to Korean CROs from the U.S. Biosecure Act, but WuXi AppTec itself has said actual business impact remains limited, leaving the pace of demand shift uncertain.
Founded and listed on KOSDAQ in 2007, BioToxTech is a leading Korean non-clinical contract research organization (CRO) specializing in safety and efficacy evaluation of pharmaceuticals, cell therapies, and chemical substances.
The company holds the largest number of Good Laboratory Practice (GLP) certification items among domestic CROs, having received U.S. FDA GLP qualified status in 2015 and OECD Mutual Joint Visit (MJV) qualification in 2010, maintaining its position as the only KOSDAQ-listed CRO in Korea.
The business is split between the parent company, which performs rodent and non-rodent toxicology testing, safety pharmacology, and bioanalysis, and non-human primate (NHP) specialist subsidiary Keyprime Research.
Established in 2021, Keyprime Research built a facility in Osong, Chungbuk that can house up to 1,100 primates simultaneously, making it the largest such facility in Korea and among the largest globally.
Overseas clients accounted for more than 60% of Keyprime Research's KRW 17.2 billion in new H1 contracts, underscoring the expansion of the company's global customer base. In contrast, the parent company's standalone business remains relatively more domestically weighted and is facing cost-ratio pressure.
Competitively, the company faces public institutions and a handful of private CROs domestically, while globally it competes with large players such as WuXi AppTec, LabCorp, and Charles River Laboratories, as well as increasingly aggressive low-cost Indian CROs.
Affiliated entities include Keyfron Bio, which specializes in bioanalysis, and Sejong Venture Partners, a bio-focused venture capital firm, giving the group a portfolio spanning much of the drug development value chain.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩9.6B | -₩1.9B | −20.0% |
| 2025Q3 | ₩11.9B | -₩1.4B | −11.5% |
| 2025Q4 | ₩14.2B | -₩97,589,843 | −0.7% |
| 2026Q1 | ₩11.9B | -₩1.8B | −15.4% |
| 2026Q2 | ₩14.5B | -₩200M | −1.3% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩37.3B | ₩800M | ₩2.7B | 2.1% | 6.2% | 183.3% |
| 2023 | ₩32.6B | -₩8.2B | -₩4.9B | −25.1% | −9.4% | 204.8% |
| 2024 | ₩41.3B | -₩8.9B | -₩6.4B | −21.5% | −16.0% | 294.5% |
| 2025 | ₩47B | -₩4.8B | ₩1.2B | −10.2% | 2.9% | 312.2% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-05
BioToxTech's consolidated revenue declined from KRW 37.3 billion in 2022 to KRW 32.6 billion in 2023, then rose for two consecutive years to KRW 41.3 billion in 2024 and KRW 47.0 billion in 2025, showing a top-line recovery.
Operating profit, however, swung from a KRW 0.8 billion gain in 2022 to losses of KRW 8.2 billion in 2023 and KRW 8.9 billion in 2024, and remained negative at KRW 4.8 billion in 2025, leaving the operating margin at -10.2%.
Full-year 2025 net income attributable to owners turned positive at KRW 1.2 billion, largely driven by a non-operating gain reflected in the KRW 5.5 billion net profit recorded in Q3 2025 alone, even as the operating result for that quarter remained a KRW 1.4 billion loss.
On a quarterly basis, Q4 2025 revenue rose to KRW 14.2 billion with the operating loss narrowing to KRW 0.1 billion, but Q1 2026 saw revenue slip back to KRW 11.9 billion and the operating loss widen again to KRW 1.8 billion.
Q2 2026 revenue recovered to KRW 14.5 billion with the operating loss shrinking to just KRW 0.2 billion, showing clear improvement at the operating level, yet net loss attributable to owners reached KRW 5.8 billion, a large divergence from the operating result.
This non-operating volatility left the trailing four-quarter (Q3 2025 through Q2 2026) net income attributable to owners at a cumulative loss of roughly KRW 4.0 billion, and the specific nature of these non-operating items would require further disclosure to clarify.
The debt ratio climbed steadily from 183.3% in 2022 to 312.2% in 2025, indicating rising financial leverage.
On the other hand, consolidated operating cash flow turned positive at KRW 6.6 billion in 2025, a marked improvement from negative KRW 7.1 billion in 2024 and negative KRW 16.2 billion in 2023, signaling a recovery in cash-generating capacity.
The non-clinical CRO market is essential infrastructure for verifying the safety and efficacy of drug candidates, having grown from USD 16.74 billion in 2021 at an 11.4% CAGR toward an estimated USD 32.01 billion by 2027.
The domestic CRO industry entered a downturn from 2021 as weakening capital-market sentiment toward biotech investment led to reduced liquidity and, in turn, lower demand for clinical and non-clinical testing. Against this backdrop, the U.S.
Biosecure Act was formally signed into law in December 2025 as Section 851 of the FY2026 National Defense Authorization Act (NDAA), restricting federal funding and contracts involving equipment or services from companies designated as biotechnology companies of concern.
Although specific company names such as WuXi AppTec were removed from the final legislation, the Korea Biotechnology Industry Organization expects this to intensify competition among Korean, Indian, Japanese, and European firms seeking to fill the U.S. market gap left by Chinese CROs.
However, at the BioKorea 2026 event in April, WuXi AppTec itself stated that the actual business impact has been limited, and recent results at both WuXi Biologics and WuXi AppTec have remained resilient, leaving the timing and scale of any spillover benefit uncertain.
In addition, while Korean CRO firms tout price competitiveness relative to Charles River Laboratories and LabCorp, Indian CROs are entering the market at even lower price points, intensifying competitive pressure.
BioToxTech is positioning its full life-cycle service capability spanning primates, rodents, and non-rodents, along with its leading number of domestic GLP certifications, as key competitive strengths, though the timing of a broader industry recovery remains unclear.
Management expects that the large order backlog secured in H1 will be recognized as revenue progressively from the second half, driving a fuller earnings recovery.
In particular, the company anticipates further profitability improvement at Keyprime Research from Q3 onward and, on that basis, has expressed hope for a full-year operating profit this year.
Keyprime Research has continued to win large overseas contracts, including a EUR 1.38 million (roughly KRW 2.4 billion) NHP GLP non-clinical testing agreement with a Europe-based antibody-drug conjugate (ADC) biotech company.
The BioToxTech parent company also maintained order momentum, with new H1 orders rising 17% year-on-year to KRW 19.8 billion. It should be noted that these optimistic projections are based on company statements, and actual results may vary depending on the timing of revenue and order recognition across quarters.
Over the longer term, a potential initial public offering (IPO) for Keyprime Research is cited as a future event to watch, though the specific timing or method has not yet been finalized.
The schedule for the U.S. government's list of biotechnology companies of concern under the Biosecure Act, and subsequent implementation guidelines, is also a variable that could affect the company's overseas order flow.
Over the trailing four quarters (Q3 2025 through Q2 2026), net income attributable to owners has remained in loss territory on a cumulative basis, meaning traditional price-to-earnings comparisons offer limited insight at this time.
The relationship between share price and book value (net assets) fluctuates between a modest discount and a modest premium depending on the calculation basis used, making it fairly sensitive to how capital structure and net asset value are computed.
The company currently maintains a no-dividend policy, which limits comparisons based on shareholder returns via dividends.
On the earnings side, the frequent shifts in direction — from a modest profit in 2022, to widening losses in 2023–2024, a return to net profit in 2025, and back to a net loss in H1 2026 — complicate valuation interpretation.
The rise in the debt ratio from around 183% in 2022 to around 312% in 2025 is another factor worth monitoring, as it could affect future interest costs or financing terms.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-05
Kyprime Research, a specialized non-human primate (NHP) subsidiary, achieved its first-ever quarterly operating profit since founding in Q2 2026, posting revenue of KRW 5.8 billion and operating profit of KRW 400 million.
Overseas customers accounted for more than 60% of new contract value in the first half, showing an expanding global demand base. The company expects this profitable trend to become more pronounced from Q3 onward.
The combined order backlog of Biotoxtech and Kyprime Research stood at KRW 60.7 billion at the end of the first half, while the parent company's order backlog also rose 18% year-on-year to KRW 43.5 billion.
If the secured order volume is sequentially reflected in revenue from the second half, it could enhance the visibility of top-line growth.
As the U.S. BIOSECURE Act was enacted as part of the FY2026 National Defense Authorization Act, interest has grown in domestic companies capable of filling the vacuum left by Chinese CROs and CDMOs in the U.S. market.
Biotoxtech is regarded as one of the few domestic companies with full life-cycle service capabilities spanning non-human primates, rodents, and non-rodents.
Quarterly net profit and loss show very large fluctuations, including net profit attributable to controlling shareholders of KRW 5.5 billion in Q3 2025 and a net loss of KRW 5.8 billion in Q2 2026.
The recurring pattern where improvement in operating profit does not necessarily translate into improved net profit could be pointed out as a factor lowering the predictability of earnings.
The debt-to-equity ratio has steadily risen from 183.3% in 2022 to 312.2% in 2025.
Given the company's history of raising funds through mezzanine instruments such as convertible bonds (CBs) and bonds with warrants (BWs), the financial burden could increase if additional financing or early redemption requests arise in the future.
WuXi AppTec stated that the actual business impact from the BIOSECURE Act is limited, and as Indian CROs are entering the market with lower prices, the expected benefits may not materialize as quickly as anticipated.
It is also assessed as still premature to clearly determine whether the domestic CRO industry itself is recovering.
Since 2021, the domestic CRO industry has experienced a downturn as demand for clinical and non-clinical trials declined due to worsening liquidity amid diminished biotech investment sentiment. If the recovery in R&D spending by biotech ventures is delayed, order momentum could weaken again.
With the debt-to-equity ratio rising into the 300% range, mezzanine instruments such as previously issued convertible bonds and bonds with warrants remain a potential source of equity dilution. Exercise of early redemption rights or the need for new financing in the future could affect shareholder value.
In addition to competition with major global CROs such as WuXi AppTec, LabCorp, and Charles River, market entry by Indian CROs offering lower prices is accelerating. If price competition intensifies, the pace of profitability improvement for domestic CROs could be constrained.
This will be a key point to check whether Keyprime Research's operating profit continues and whether consolidated full-year operating results could turn positive.
The U.S. Office of Management and Budget (OMB) is expected to officially publish its list of Biosecure Act 'biotechnology companies of concern,' which could clarify the scope of potential benefits for Korean CROs.
Detailed implementation guidelines are expected following the designation of companies of concern, with actual enforcement discussed as likely occurring around late 2027 to 2028, making the concretization of this timeline worth monitoring.
Any disclosures on additional major overseas contracts for Keyprime Research or progress toward a potential IPO would provide reference points for assessing medium-to-long-term growth.
BioToxTech showed signs of operating-level improvement in H1 2026, supported by revenue growth and the first-ever quarterly profit at subsidiary Keyprime Research.
However, annual and quarterly net income has repeatedly swung between profit and loss due to significant non-operating volatility, meaning operating improvements have not directly translated into consistent net income gains.
A large order backlog and a growing share of overseas clients improve revenue visibility for the second half and beyond, but this comes alongside rising financial leverage, reflected in a climbing debt ratio. The U.S.
Biosecure Act is cited as a medium-to-long-term opportunity for Korea's CRO industry, though WuXi AppTec and other Chinese firms have indicated the actual impact remains limited so far, leaving the size and timing of any spillover benefit uncertain.
Shifting competitive dynamics, including the rise of low-cost Indian CROs, are another factor to watch. Overall, this report has presented bullish and bearish factors in balance based on confirmed disclosures and reported facts, leaving investment judgment to the reader.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.